Brussels- The first in-depth opportunity to understand, debate and influence new European Commission (EC) legislative changes and their implications-the Proposals for new Pharmaceutical Legislation EU update meeting-is being hosted by The Organisation for Professionals in Regulatory Affairs (TOPRA) on 25-26 February 2009.
Over the two days of this meeting nearly 20 speakers from the European Commission, pan-European national agencies, national authorities and industry will discuss the European Pharmaceutical Package announced by the European Commission on 10th December 2008 and give their view on the new legislation proposals.
Issues discussed at the conference will include the development, purpose and expected outcomes of the pharmaceutical package, counterfeit medicines, information to patients and pharmacovigilance. Please find
attached the draft programme which gives further detail.
This conference has relevance for all of industry, health agencies and other stakeholders. It should be attended by anyone that the 'Pharma Package' will affect.
The organisers would like to take this opportunity to invite you to conference and take advantage of a number of free press passes that are available.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.